Kolf 2.1 J (TARDBP M337V WT/SNV)
WTSIi018-B-18
General
Cell Line |
|
| hPSCreg name | WTSIi018-B-18 |
| Cite as: | WTSIi018-B-18 |
| Alternative name(s) |
Kolf 2.1 J (TARDBP M337V WT/SNV)
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
WTSIi018-B-21 (Kolf 2.1 J (TARDBP M337V SNV/SNV)) WTSIi018-B-22 (Kolf 2.1 J (TARDBP Q331K WT/SNV)) WTSIi018-B-23 (Kolf 2.1 J (TARDBP Q331K SNV/SNV)) WTSIi018-B (HPSI0114i-kolf_2) UQi001-A-1 (C11-TDP43-A382T) WTSIi018-B-24 (Kolf 2.1 J (FUS R495X WT/SNV)) WTSIi018-B-25 (Kolf 2.1 J (FUS R495X SNV/SNV)) WTSIi018-B-26 (Kolf 2.1 J (FUS R521H WT/SNV)) WTSIi018-B-27 (Kolf 2.1 J (FUS R521H SNV/SNV)) WTSIi018-B-1 (HPSI0114i-kolf_2-C1) WTSIi018-A (HPSI0114i-kolf_3) UCSFi001-A-74 (FUS-P525L HET 2D1) UCSFi001-A-75 (FUS-P525L HOM 2D2) UCSFi001-A-72 (FUS-R521G HET 2B10, LSUHSi004-A-72) UCSFi001-A-73 (FUS-R521G HOM 1D9) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi010-C-7 (BIONi010-C Trem2 R47H) BIONi010-C-8 (BIONi010-C Trem2 T66M, #Y5-80) BIONi010-C-9 (BIONi010-C CD33 KO) BIONi010-C-17 (BIONi010-C TREM2 KO) CBIGi001-A-1 (PRKN-KO, PRKN-KO/AIW002-02) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) WAe001-A-76 (H1-RNF1-/-) CBIGi001-A-2 (PINK1-KO, PINK1-KO/AIW002-02) CBIGi001-A-3 (PINK1-KO/PRKN-KO/AIW002-02, PINK1-KO/PRKN-KO) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-5 (BIONi010-C CD33 E2del #N14 P26) |
| Last update | 6th March 2024 |
| User feedback | |
Provider |
|
| Generator |
Max Delbrück Center Berlin Buch (MDC)
Contact:
Jackson Laboratories (JAX) |
| Owner | Wellcome Sanger Institute (WTSI) |
| Distributors | |
| Derivation country | United Kingdom |
External Databases |
|
| BioSamples | SAMEA115377549 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | White - White British |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA2398402 |
| HipSci | HPSI-kolf |
Ethics
Also have a look at the ethics information for the parental line
WTSIi018-B
.
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
WTSIi018-B.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Medium |
Other medium:
Base medium: StemFlex
Main protein source: Serum concentration: % |
Characterisation
No characterisation data could be found for this subclone. Please open parental cell line WTSIi018-B .Genotyping
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.